AYTU earnings analysis
What we found in AYTU's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Aytu BioPharma's Q3 fiscal 2026 report shows a significant decline in both revenue and EPS compared to prior periods. Revenue totaled $12.4 million, missing consensus estimates, while EPS registered at -$0.53, highlighting ongoing challenges, particularly in the ADHD portfolio due to higher competition and generic pressures. Management has pivoted focus towards the newly launched EXXUA product amidst these headwinds.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline
- Q3 2026 revenue of $12.4M is down $6.0M, or 33%, from Q3 2025.
- Gross Margin Compression
- Gross profit decreased to $7.6M in Q3 2026 from $12.8M, with gross margin declining to 61% from 69%.
- Increased Operating Expenses
- Operating expenses rose by $1.3M to $11.7M in Q3 2026 compared to Q3 2025.
- EXXUA Launch
- Successful launch of EXXUA contributed $2.4 million to revenue in Q3 2026.
- Reduced Interest Expense
- Interest expense fell to $436K in Q3 2026 from $900K in Q3 2025, a 52% decrease.
- Shift in Marketing Focus
- Management has shifted marketing efforts towards EXXUA, leading to reduced spending in ADHD products.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Continued Revenue Decline
- Overall net revenue declined by 19% in the first nine months of 2026, primarily from ADHD portfolio challenges.
- Generics Competition
- The launch of a generic version of an ADHD product late in Q2 has contributed to decreased ADHD revenue.
- Losses from Operations
- Net loss from continuing operations reached $5.6M in Q3 2026, worsening from previous year.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.53
- Gross margin
- 61%
- Segment
- EXXUA: $2.4M
- Segment
- ADHD: $9.1M
- Segment
- Pediatric: $3.1M
What they said about what is next.
Management has not provided specific numeric guidance for future quarters.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 3, 2026
- Aytu reported net revenue of $15,165,000 for the quarter ended December 31, 2025 (down from $16,221,000 in the year‑ago quarter) and GAAP diluted EPS of $(1.05) versus $0.11 a year earlier. Gross margin contracted to…
- 10-K · September 23, 2025
- Aytu is transitioning to a focused commercial-stage pharmaceutical company centered on an anticipated EXXUA (gepirone) U.S. launch in Q4 2025 while growing its prescription business (Adzenys/Cotempla ADHD portfolio and…
- 10-Q · May 14, 2025
- Aytu reported quarterly net revenue of $18,452,000 for the three months ended March 31, 2025, up from $14,025,000 in the prior-year quarter, and swung to operating income of $2,421,000 (13.1% margin) from an operating…
- 10-Q · February 12, 2025
- Aytu reported quarterly net revenue of $16,221 (amounts in the filing are in thousands) for the three months ended December 31, 2024, down from $18,748 in the prior-year quarter but modestly above street consensus.…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AYTU makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever